All articles tagged with #alk mutation
Lung cancer is increasingly diagnosed in healthy, non-smokers—often younger women—driven by genetic changes like ALK and environmental factors such as air pollution and burn-pit toxins; experts urge expanding screening beyond smoking history and highlight targeted therapies that can turn advanced disease into a manageable condition.
Pfizer anticipates its lung cancer drug Lorbrena will surpass $1 billion in annual sales by 2030, driven by strong five-year clinical trial data showing significant disease progression-free survival rates in patients with ALK-positive advanced lung cancer. The drug, which outperforms Pfizer's earlier treatment Xalkori, has shown particularly promising results in patients with brain metastases and is expected to see substantial market growth, especially in China.
Pfizer's drug Lorbrena significantly extends the life expectancy of patients with ALK-positive non-small cell lung cancer, a rare and particularly deadly form of the disease. New research shows that 60% of patients treated with Lorbrena were still alive after five years, compared to 8% of those treated with crizotinib. Lorbrena also effectively prevents brain metastasis, a common and severe complication of ALK-positive lung cancer. However, the drug may cause more neurotoxic side effects, which can be managed by adjusting the dosage.